Clinical News

Going beyond genetics yields clues to challenging childhood brain cancer

By Clinical | No Comments

25 November 2016

Cancer is often seen as a disease of genetic changes.  But one type of childhood brain tumour has stymied efforts to identify a recurring genetic defect.

Now, new research suggests changes at the epigenetic level – specifically alterations in proteins that affect gene expression, rather than genetic mutations – could be driving childhood ependymomas.

Read more >>

Diagnostic Performance and Safety of Positron Emission Tomography Using 18F-Fluciclovine in Patients with Clinically Suspected High- or Low-grade Gliomas

By Clinical | No Comments

25 November 2016

A Multicenter Phase IIb Trial

The study objective was to assess the diagnostic performance of positron emission
tomography (PET) for gliomas using the novel tracer 18F-fluciclovine (anti-[18F]FACBC) and to
evaluate the safety of this tracer in patients with clinically suspected gliomas.

Read more >>

Upfront Chemoradiation Shown to Improve Survival Over Radiotherapy Alone in Low-Grade Glioma

By Clinical | No Comments

25 November 2016

Upfront, predominantly temozolomide-based, chemoradiotherapy conferred an overall survival benefit over radiotherapy alone in a population of patients with World Health Organization grade II gliomas

This outcome of a single-institution, retrospective review covering a 13-year period was reported at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology, from November 17 – 20.

Read more >>

Expert Discusses Promising ABT-414 Trial Results in EGFR-Amplified, Recurrent GBM

By Clinical | No Comments

21 November 2016

A phase I trial of the antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma (GBM).

Lead author Martin van den Bent, MD, PhD, of the Erasmus MC Cancer Center in Rotterdam, the Netherlands, is presenting the findings during the 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) being held November 17-20, 2016, in Scottsdale, Arizona.

Read more >>

Checkpoint Inhibitors Show Promise in Glioblastoma

By Clinical | No Comments

21 November 2016

Findings from separate trials exploring the PD-1 inhibitor pembrolizumab (Keytruda) and the PD-L1 inhibitor durvalumab (MEDI4736) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme (GBM), based on encouraging efficacy signals and safety data with the two agents reported by David Reardon, MD, at the 21st Society for Neuro-Oncology (SNO) Annual Scientific Meeting.

Read more >>